Detalles de la búsqueda
1.
Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved.
Immunity
; 41(6): 909-18, 2014 Dec 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-25526306
2.
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.
Immunity
; 38(1): 176-86, 2013 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-23313589
3.
Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency.
J Virol
; 94(4)2020 01 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-31776278
4.
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.
PLoS Pathog
; 13(2): e1006182, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28235027
5.
Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
J Infect Dis
; 215(8): 1255-1263, 2017 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28329190
6.
Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion.
J Virol
; 87(3): 1554-68, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23175357
7.
Innate immune cell activation after HIV-1 vaccine administration is associated with increased antibody production.
Front Immunol
; 15: 1339727, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38420129
8.
Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.
J Virol
; 86(22): 12105-14, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22933284
9.
Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials.
J Infect Dis
; 205(12): 1806-10, 2012 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22492863
10.
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.
J Infect Dis
; 206(3): 431-41, 2012 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22634875
11.
Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability.
AIDS
; 37(10): 1519-1524, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37260254
12.
ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone.
JCI Insight
; 8(9)2023 05 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37154156
13.
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors.
J Virol
; 85(19): 9998-10009, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21795340
14.
IFNL4 genotype influences the rate of HIV-1 seroconversion in men who have sex with men.
Virulence
; 13(1): 757-763, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35481423
15.
No association of a risk variant for severe COVID-19 with HIV protection in three cohorts of highly exposed individuals.
PNAS Nexus
; 1(3): pgac138, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36741450
16.
Phylodynamics of HIV-1 from a phase-III AIDS vaccine trial in North America.
Mol Biol Evol
; 27(2): 417-25, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19864468
17.
Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus.
J Virol
; 84(21): 11200-9, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20702624
18.
Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.
J Infect Dis
; 202(4): 595-605, 2010 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20608874
19.
AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.
Vaccine
; 39(33): 4641-4650, 2021 07 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34229888
20.
Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies.
J Virol
; 83(15): 7728-38, 2009 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-19474108